LogicBio Therapeutics, Inc. (LOGC) is headed up in the market in today’s trading session. The stock, one that is focused in the biotechnology industry, is currently trading at $16.21 after gaining 9.45% so far today. When it comes to biotech companies, there are quite a few factors that have the ability to lead to price movement in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines centered around LOGC:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nonetheless, any time investors are making an investing decision, investors should look into much more than just news, this is especially the case in the speculative biotechnology space. Here’s what’s happening in regard to LogicBio Therapeutics, Inc..

Returns That LOGC Investors Have Seen

Although a gain in a single session, like the move that we’re seeing from LogicBio Therapeutics, Inc. might make some investors happy, a single session gain by itself should not be the reason for a decision to, or not to, invest in a stock. It is generally a good idea to look into trends just a single trading day. When it comes to LOGC, below are the returns that we have seen:

  • Past 5 Trading Sessions – Throughout the last week, LOGC has seen a change in value amounting to 9.90%.
  • Past Month – The monthly returns from LogicBio Therapeutics, Inc. has been 20.61%.
  • Quarterly – Throughout the last 3 months, the company has produced a return on investment that comes to 64.24%
  • Past 6 Months – Throughout the previous 6 months, we’ve seen a change of 14.64% from the company.
  • Year To Date – Since the close of last year LOGC has generated a return on investment of 55.87%.
  • Full Year – Finally, throughout the past year, investors have seen a change that works out to 0 from LOGC. In this period, the stock has traded at a high of -9.94% and a low price of 141.94%.

Ratios Worth Watching

Looking at a few ratios associated with a company generally gives investors a view of how risky and/or potentially profitable a pick may be. Here are some of the most important ratios to think about when digging into LOGC.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it shows that more investors have a belief that the value of the stock is going to go down. Throughout the sector, biotechnology stocks tend to have a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the sector. Nonetheless, when it comes to LogicBio Therapeutics, Inc., the stock’s short ratio clocks in at 4.65.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure If a company is able to pay its debts when they come due with only quick assets or current assets. In the biotechnology sector, companies rely on the continuation of investor support, the quick and current ratios can be bad. Nonetheless, several good picks in the biotechnology industry do have great current and quick ratios. When it comes to LOGC, the quick and current ratios add up to 19.70 and 19.70 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the share price of the stock. In the case of LogicBio Therapeutics, Inc., that ratio is 3.26.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is an important ratio to think about. In this case, the cash to share value ratio works out to 3.53.

How Analysts Feel About LogicBio Therapeutics, Inc.

While it’s not a good idea to blindly follow the opinions of analysts, it is a smart idea to use their analysis when validating your own before making investment decisions in the biotechnology industry. Below are the most recent moves that we’ve seen from analysts when it comes to LOGC.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-01-19 Initiated ROTH Capital Buy $26

Is Big Money Interested in LogicBio Therapeutics, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in LOGC, here’s what we’re seeing:

  • Institutional Investors – At the moment, institutional investors own 62.40% of LogicBio Therapeutics, Inc.. On the other hand, it’s worth considering that the ownership held by institutions has seen a move in the amount of -0.32% in the last quarter.
  • Insider Holdings – as it relates to insiders, insiders of the company currently own 26.97% of the company. Insider ownership of the company has moved 0 throughout the last quarter.

Looking At Share Counts

Traders seem to have a heavy interest in the counts of shares both outstanding and available. With respect to LogicBio Therapeutics, Inc., currently there are 20.55M with a float of 15.26M. These numbers mean that of the total of 20.55M shares of LOGC that are out there today, 15.26M are able to be traded by the public.

I also find it important to look at the short float. Think about it, if a high percentage of the float is sold short, the overall opinion among investors is that the company is going to fall hard. In regard to LOGC, the short percentage of the float is currently 0.63%. Most traders believe that a concerning short percent of the float is any percentage over 40%. Nonetheless, I have found that a short ratio over 26% is usually a a play that could prove to be very risky.

What We’ve Seen In Financial Results

What have ween seen from LOGC in terms of financial results?Here’s what we’ve seen:

  • Analyst Expectations – At the moment, Wall Street analysts are expecting that LogicBio Therapeutics, Inc. will generate EPS that totals up to be -1.85, with -0.40 being announced in the next financial report. Although this information is not associated with earnings, because we are chatting on the topic of analysts, LogicBio Therapeutics, Inc. is currently graded as a 1.60 considering a scale that ranges from 1 to 5 where 1 is the worst possible analyst grade and 5 is the best.
  • 5-Year Sales – In the past half decade, LogicBio Therapeutics, Inc. has created a change in sales volume that works out to 0. Earnings per share in the past 5 years have experienced a change of 0.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is often represented in the world of humans, LogicBio Therapeutics, Inc. has seen a earnings change by 87.40%. LogicBio Therapeutics, Inc. has also experienced movement with regard to sales volume in the amount of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an AI. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings actually play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but I am able to learn much faster when I have a teacher. If you would to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below this article and I will use it to serve you better!